November 13, 2019
16/11/2019
November 13, 2019
LA JOLLA, CA Scientists at Calibr, the drug development arm of Scripps Research, have found what may be the beginnings of a new approach to treating diabetes. And they found it in an unexpected place: a drug that's currently used for a form of breast cancer.
The discovery has jumpstarted efforts to refine the drug for non-cancer diseases and highlights the value of assessing approved medicines for unexpected therapeutic benefits. The study appears in Nature Communications.
The speed of the translation and early proof-of-concept in animals was perhaps the most exciting part of the project, says Matthew Tremblay, PhD, chief operating officer of Calibr and Scripps Research, and a senior author of the study. We were able to find a compound very quickly that we could deploy as a tool in mouse models of diabetes. And because the drug already has FDA approval, we were able to understand its selectivity and pharmacology very readily to drive the program in a preclinical setting.
The drug, neratinib, was shown to protect insulin-producing beta cells in the pancreas. The loss of these cells is a hallmark of both forms of diabetes: type 1, an autoimmune disease that typically emerges early in life; and type 2, the adult-onset form influenced by both genetics and lifestyle. Neratinib is already widely used as a targeted drug for early stage breast cancer, with efficacy for patients whose tumors test positive for the HER2 gene.
Tremblay says the discovery came about through a collaboration facilitated by JDRF (formerly the Juvenile Diabetes Research Foundation), a nonprofit organization dedicated to finding a cure for type 1 diabetes. As part of a platform partnership, JDRF has introduced Calibr to researchers across the globe to translate innovative discoveries into potential new medicines.
The work described in Nature Communications is the result of Calibr's partnership with Kathrin Maedler, PhD, Amin Ardestani, PhD, and their colleagues at the University of Bremen in Germany. The team uncovered that an enzyme known as MST1, which controls cell development and survival, played a key role in activating cell signals that lead to the death or dysfunction of pancreatic beta cells.
The researchers believed that if they could find a way to block or reduce those damaging signals, they may be able to protect beta cells and stave off diabetes. Through prior work together, JDRF was aware of Calibr's unique drug-repurposing and translational capabilities.
Dr. Maedler came to us with an actionable approach for diabetes, Tremblay says. We brought the drug discovery tools to bear, and rapidly found a chemical inhibitor of this particular mechanism that appears to play a key role in the development of disease.
More than 422 million people globally have diabetes, according to the World Health Organization, and an estimated 1.6 million deaths were attributed to the disease in 2016. It is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation.
Calibr identified neratinib using high-throughput screening of drug compounds known as kinase inhibitors, which are often used to treat cancer but also have other therapeutic properties.
Calibr and University of Bremen found that treating diabetic mice for 30 days with neratinib markedly restored beta cell survival and function and prevented severe increases in blood glucose over time. A robust pro-survival effect was also observed in human islets, which are areas of the pancreas that contain beta cells. Prior to the study, neratinib's ability to inhibit MST1 signaling and protect beta cells was not known.
Though the research is just now being published, most of the work was completed before 2017. Calibr has since focused on optimizing neratinib's properties for diabetes and other chronic degenerative diseases. This means letting the drug's anti-cancer properties fall away and diminishing gastrointestinal side effects, among other things.
For chronic, non-terminal diseases where treatment is prolonged, the side effect profile must be pristine, says Weijun Shen, PhD, Calibr's director of metabolic disease and a senior author of the study.
Notably, this project served as one of several inspirations for Calibr in 2018 to build and deploy its ReFRAME drug repurposing collection, an extensive library of nearly all existing, safe small-molecule drugs shown to be appropriate for direct use in humans. The collection offers great potential for finding therapies more quickly and cost-effectively.
Repurposing of FDA-approved drugs has been a topic of great interest amidst the escalating costs of new drug development, particularly in the case of diseases with high-unmet medical need, such as type 1 diabetes, the authors say in the study.
The discovery of neratinib's ability to protect beta cells amounts to an accelerated path to a preclinical proof of concept and a firm basis for follow-up work on next-generation compounds that could add to the treatment options for diabetes, they conclude.
Authors of the article Neratinib protects pancreatic beta cells in diabetes, include Amin Ardestani, Sijia Li, Karthika Annamalai, Blaz Lupse, Shirin Geravandi, Aleksandra Dobrowolski, Shan Yu, Siying Zhu, Tyler D. Baguley, Murali Surakattula, Janina Oetjen, Lena Hauberg-Lotte, Raquel Herranz, Sushil Awal, Delsi Altenhofen, Van Nguyen-Tran, Sean Joseph, Peter G. Schultz, Arnab K. Chatterjee, Nikki Rogers, Matthew S. Tremblay, Weijun Shen and Kathrin Maedler.
The work was supported by JDRF through a Translational Academic Research Partnership.
Diabetes, Obesity and Metabolic Disorders Tr
LINK: | https://www.scripps.edu/news-and-events/press-room/2019/20191113-calib... |
See more stories from scripps |
More from Scripps
12/04/2024
April 11, 2024
Scripps Research chemists devise easier new method for making a common type of building block for drugs Scientists transform simple linear amines into saturated...
06/04/2024
April 05, 2024
A simple, inexpensive way to make carbon atoms bind together A Scripps Research team uncovers a cost-effective method for producing quaternary carbon molecules,...
04/04/2024
April 03, 2024
Developing a vaccine for the zombie drug xylazine Scripps Research chemical biologists design an early proof-of-concept vaccine that could lead to the first...
30/03/2024
March 29, 2024
How blocking a neural receptor responsible for addiction could reduce alcohol use A Scripps Research team found that a new therapeutic that targets the kappa op...
13/03/2024
March 13, 2024
New computational strategy boosts the ability of drug designers to target proteins inside the membrane Customized-design approach could streamline the design of...
29/02/2024
February 29, 2024
Scripps Research scientists reveal how first cells could have formed on Earth New phospholipid discovery brings researchers closer to understanding how primordi...
29/02/2024
February 28, 2024
How molecular handedness emerged in early biology Scripps Research chemists fill a major gap in origin-of-life theories. February 28, 2024 LA JOLLA, CA Mole...
22/02/2024
February 21, 2024
Snaking toward a universal antivenom Scripps Research scientists discovered antibodies that protect against a host of lethal snake venoms. February 21, 2024 ...
06/02/2024
February 06, 2024
Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases AbbVie...
26/01/2024
January 25, 2024
Re-energizing mitochondria to treat Alzheimer's disease Scripps Research team restored neuron-to-neuron connections in human cells. January 25, 2024 LA JO...
24/01/2024
January 04, 2024
100 years of Science Changing Life: Scripps Research celebrates a century of transforming human health For the last century, institute leaders and renowned scie...
23/01/2024
January 23, 2024
New technology lets researchers track brain cells' off switches The method could shed light on what goes awry in numerous brain conditions when neurons ar...
09/01/2024
January 08, 2024
Three decades of giving: Announcing the Calibr-Skaggs Institute for Innovative Medicines The ALSAM Foundation, founded by the Skaggs family, provides lasting g...
04/01/2024
January 03, 2024
Life science entrepreneur Gene Lay joins Scripps Research Board of Directors Lay, founder of the global biotech company BioLegend, brings invaluable experience ...
21/12/2023
December 20, 2023
Taming a plant-derived toxin Scripps Research team modifies the traditional poison picrotoxinin for potential neurological drugs and anti-parasite treatments. ...
19/12/2023
December 18, 2023
Scripps Research Executive Vice President Eric Topol gives TED talk on transformative power of AI in medicine Topol provides an overview of how AI models can i...
13/12/2023
December 12, 2023
New AI-powered algorithm could better assess people's risk of common heart condition Early detection of atrial fibrillation can reduce the risk of stroke an...
07/12/2023
December 06, 2023
Nanoparticle flu vaccine design shows promise in early tests Scripps Research-designed vaccine could provide broad, enduring protection against influenza A str...
16/11/2023
November 15, 2023
Numerous Scripps Research scientists named Highly Cited Researchers Clarivate's annual, global list represents researchers who have demonstrated significant...
07/11/2023
November 06, 2023
Multiple sclerosis drug invented at Scripps Research slows long-term devastating disease progression Late-breaking data reinforces the effectiveness and safety ...
05/10/2023
October 04, 2023
Keren Lasker named a 2023 Moore Inventor Fellow The prestigious award will support Lasker's inventive research in membraneless organelles and their applica...
22/09/2023
September 21, 2023
Michael Bollong named a 2023 Amgen Young Investigator The prestigious award will support Bollong's research identifying new molecular targets and therapeuti...
09/09/2023
September 08, 2023
Philip Dawson receives 2024 American Chemical Society National Award Dawson is honored with the Arthur C. Cope Late Careers Scholar Award for his foundational c...
07/09/2023
September 06, 2023
Scripps Research chemists devise a method for C-H activation of alcohols The method represents a new toolkit for making drugs and other compounds. September 06...
31/08/2023
August 30, 2023
Scripps Research receives $1.5M to surveil infectious disease threats in wastewater Bill & Melinda Gates Foundation award to support the development of multi-pa...
16/08/2023
August 16, 2023
How cold temperatures trigger the brain to boost appetite Scripps Research scientists' discovery could lead to new weight loss and metabolic health treatmen...
08/08/2023
August 07, 2023
Human antibody that targets carfentanil, fentanyl and related opioids reverses overdose effects in preclinical study Scripps Research-developed antibody therapy...
04/08/2023
August 03, 2023
How sensory neurons impact the gut Scripps Research scientists show that the receptor PIEZO2 in sensory neurons controls gut motility and transit time, which a...
26/07/2023
July 26, 2023
AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets The expanded strategic collaboration will advan...
23/07/2023
July 21, 2023
Scripps Research scientists develop AI-based tracking and early-warning system for viral pandemics Machine-learning system effectively predicts emergence of pro...
19/07/2023
July 19, 2023
Monitoring T cells may allow prevention of type 1 diabetes Scripps Research study shows that analyzing T cells in blood samples could be used to select at-risk ...
19/07/2023
July 18, 2023
Scripps Research mourns passing of leading organic chemist Albert Eschenmoser Eschenmoser pioneered key reactions in synthetic chemistry and shaped the understa...
15/06/2023
June 14, 2023
Scripps Research awarded $46.8 million by NIH to promote human health through innovative translational science and training The Translational Institute is harne...
13/06/2023
June 13, 2023
Scripps Research's Danielle Grotjahn named 2023 Pew Scholar in the Biomedical Sciences The award will support Grotjahn's study of how cells assemble the...
31/05/2023
May 31, 2023
Crossing the ring: new method enables C-H activation across saturated carbocycles Scripps Research chemists add another powerful tool to their molecular editin...
24/05/2023
May 23, 2023
Scripps Research develops behind-the-scenes tool for better biomedical data discovery The new resource makes datasets more discoverable for life science communi...
19/05/2023
May 15, 2023
Scripps Research neuroscientist Hollis Cline elected to American Academy of Arts and Sciences Cline is recognized for her discoveries about the role of sensory ...
19/05/2023
May 18, 2023
Scripps Research's Skaggs Graduate School awards doctoral degrees to 31st graduating class Commencement ceremony will be livestreamed via Zoom and on instit...
13/05/2023
May 12, 2023
A better route to benzocyclobutenes, sought-after building blocks for drugs Scripps Research chemists devise a new, C-H activation-based method for the synthesi...
09/05/2023
May 08, 2023
Renowned Scripps Research professor Jeffery Kelly elected to National Academy of Sciences Kelly's groundbreaking work on protein misfolding has led to thera...
28/04/2023
April 27, 2023
Mirror-image molecules pave new path for cancer drug discovery By comparing how mirror image versions of small molecules impact clusters of proteins, Scripps R...
22/04/2023
April 21, 2023
How alcohol consumption contributes to chronic pain A Scripps Research team showed how both alcohol intake and alcohol withdrawal can lead to increased pain and...
21/04/2023
April 20, 2023
Xin Jin receives dual awards to study autism risk genes in neurodevelopment Major grants from the National Institutes of Health and California Institute for Reg...
20/04/2023
April 19, 2023
Trim the sugar: New HIV vaccine design improves immune response Scripps Research vaccine candidate headed for clinical trials. April 19, 2023 LA JOLLA, CA A...
18/04/2023
April 17, 2023
Therapeutic can seek and destroy potent opioid to treat overdoses Scripps Research chemists developed a new biologic to work against the synthetic opioid carfen...
07/03/2023
March 06, 2023
How heavy alcohol consumption increases brain inflammation The findings by a Scripps Research team point toward a potential new drug target for treating alcohol...
02/03/2023
March 01, 2023
Scientists find human antibodies that can block multiple coronaviruses including SARS-CoV-2 Results from a Scripps Research and UNC team pave the way for a vacc...
28/02/2023
February 28, 2023
$10 million grant funds Scripps Research Alcohol Research Center through its 50th year The five-year grant supports research into the neurobiology of alcohol us...
28/02/2023
February 27, 2023
Immune system drug shows promise in treating alcohol use disorder, a Scripps Research clinical trial reports Scientists at Scripps Research found that apremilas...
23/02/2023
February 16, 2023
Chemically poisoned protein acts as a molecular switch to spur cancer formation The discovery triggered development of a new potential drug to eliminate tumor...